Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
Ye JiBaoyan WangGuangyan WuYepeng ZhangQing WangMin ZhouPublished in: Therapeutic advances in chronic disease (2023)
Rivaroxaban-based dual antithrombotic therapy significantly reduced the occurrence of MACE in patients with LE-PAD without increasing major bleeding events. High-risk patients benefited from the dual antithrombotic therapy.
Keyphrases
- atrial fibrillation
- peripheral artery disease
- end stage renal disease
- venous thromboembolism
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- pulmonary embolism
- risk assessment
- peritoneal dialysis
- prognostic factors
- stem cells
- coronary artery bypass grafting
- coronary artery disease
- acute coronary syndrome
- cell therapy
- clinical evaluation